RU2221789C2 - Замещенные сульфонилцианамиды и фармацевтическая препаративная форма - Google Patents

Замещенные сульфонилцианамиды и фармацевтическая препаративная форма Download PDF

Info

Publication number
RU2221789C2
RU2221789C2 RU2000130719/04A RU2000130719A RU2221789C2 RU 2221789 C2 RU2221789 C2 RU 2221789C2 RU 2000130719/04 A RU2000130719/04 A RU 2000130719/04A RU 2000130719 A RU2000130719 A RU 2000130719A RU 2221789 C2 RU2221789 C2 RU 2221789C2
Authority
RU
Russia
Prior art keywords
hydrogen
alkyl
independently
carbon atoms
sulfonylcyanamides
Prior art date
Application number
RU2000130719/04A
Other languages
English (en)
Other versions
RU2000130719A (ru
Inventor
Андреас ВАЙХЕРТ (DE)
Андреас Вайхерт
Ханс Йохен ЛАНГ (DE)
Ханс Йохен Ланг
Штефан ПЕТРИ (DE)
Штефан Петри
Ян-Роберт ШВАРК (DE)
Ян-Роберт Шварк
Хайнц-Вернер КЛЕЕМАНН (DE)
Хайнц-Вернер КЛЕЕМАНН
Сабине ФАБЕР (DE)
Сабине Фабер
Ханс-Вилли ЯНСЕН (DE)
Ханс-Вилли ЯНСЕН
Original Assignee
Авентис Фарма Дойчланд Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Авентис Фарма Дойчланд Гмбх filed Critical Авентис Фарма Дойчланд Гмбх
Publication of RU2000130719A publication Critical patent/RU2000130719A/ru
Application granted granted Critical
Publication of RU2221789C2 publication Critical patent/RU2221789C2/ru

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/68—Halogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/70—One oxygen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/84—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/91—Nitro radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

Описывают замещенные сульфонилцианамиды общей формулы (I), где Х означает
Figure 00000001
R(1) - алкил с 1, 2, 3, 4, 5, 6, 7 или 8 С-атомами или СаН2а-фенил, причем фенильная часть не замещена, а = 0; R(2) и R(3) независимо друг от друга C1, CO-R(24), R(24) - водород, OR (26); R-(26) - алкил с 1, 2, 3, 4, 5, 6, 7 или 8 С-атомами или R(2) и R(3) независимо друг от друга -SOf-R(37); R(37) - алкил с 1, 2, 3, 4, 5, 6, 7 или 8 С-атомами; f = 0; Y - CR(16)R(17), SO2; R(16) - водород; R(17) - водород; R(13), R(14), R(15) - водород. Описывается фармацевтическая препаративная форма, являющаяся ингибитором натрийзависимого бикарбонат/хлоридного обмена, содержащая эффективное количество соединения формулы (1). Технический результат - соединения являются ингибиторами натрийзависимого бикарбонат/хлоридного обмена. 2 с. и 2.з.п. ф-лы.

Description

Текст описания в факсимильном виде (см. графический материал)л

Claims (4)

1. Замещенные сульфонилцианамиды общей формулы (I)
Figure 00000073
в которой Х означает
Figure 00000074
R(1) - алкил с 1, 2, 3, 4, 5, 6, 7 или 8 С-атомами или СаН2а-фенил, причем фенильная часть незамещена, а = 0;
R(2) и R(3) - независимо друг от друга Cl, CO-R(24), R(24) - водород, OR(26), R(26) - алкил с 1, 2, 3, 4, 5, 6, 7 или 8 С-атомами, или R(2) и R(3) независимо друг от друга -SOf-R(37), R(37) алкил с1, 2, 3, 4, 5, 6, 7 или 8 С-атомами, f = 0;
Y -CR(16)R(17), SO2, R(16) - водород, R(17) - водород;
R(13), R(14), R(15) - независимо друг от друга водород.
2. Замещенные сульфонилцианамиды общей формулы (I) по п.1, в которой Х означает
Figure 00000075
R(1) - алкил с 1, 2, 3 или 4 С-атомами или CaH2a-фенил, причем фенильная часть незамещена, а = 0;
R(2) и R(3) - независимо друг от друга Cl, CO-R(24), R(24) - водород, OR(26), R(26) - алкил с 1, 2, 3 или 4 С-атомами, или R(2) и R(3) - независимо друг от друга -SOf-R(37), R(37) - алкил с 1, 2, 3 или 4 С-атомами, f = 0;
Y -CR(16)R(17), SO2, R(16) - водород, R(17) - водород, R(13), R(14), R(15) - независимо друг от друга водород.
3. Замещенные сульфонилцианамиды общей формулы (I) по п.1 или 2, в качестве ингибитора натрийзависимого бикарбонат/хлоридного обмена.
4. Фармацевтическая препаративная форма, являющаяся ингибитором натрийзависимого бикарбонат/хлоридного обмена, отличающаяся тем, что она содержит эффективное количество соединения формулы (I).
RU2000130719/04A 1998-05-06 1999-04-30 Замещенные сульфонилцианамиды и фармацевтическая препаративная форма RU2221789C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19820064.1 1998-05-06
DE19820064A DE19820064A1 (de) 1998-05-06 1998-05-06 Substituierte Sulfonylcyanamide, Verfahren zu ihrer Herstellung und ihre Verwendung als Medikament

Publications (2)

Publication Number Publication Date
RU2000130719A RU2000130719A (ru) 2003-01-27
RU2221789C2 true RU2221789C2 (ru) 2004-01-20

Family

ID=7866747

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2000130719/04A RU2221789C2 (ru) 1998-05-06 1999-04-30 Замещенные сульфонилцианамиды и фармацевтическая препаративная форма

Country Status (27)

Country Link
US (1) US6573288B1 (ru)
EP (1) EP1076651B1 (ru)
JP (1) JP4546644B2 (ru)
KR (1) KR20010043304A (ru)
CN (1) CN1177829C (ru)
AR (1) AR016255A1 (ru)
AT (1) ATE293606T1 (ru)
AU (1) AU756844B2 (ru)
BR (1) BR9911009A (ru)
CA (1) CA2331863A1 (ru)
DE (3) DE19820064A1 (ru)
DK (1) DK1076651T3 (ru)
ES (1) ES2241326T3 (ru)
HK (1) HK1038008A1 (ru)
HR (1) HRP20000746A2 (ru)
HU (1) HU225377B1 (ru)
ID (1) ID28020A (ru)
IL (1) IL139264A (ru)
NO (1) NO317886B1 (ru)
NZ (1) NZ507964A (ru)
PL (1) PL344041A1 (ru)
PT (1) PT1076651E (ru)
RU (1) RU2221789C2 (ru)
SK (1) SK16582000A3 (ru)
TR (1) TR200003248T2 (ru)
WO (1) WO1999057102A1 (ru)
ZA (1) ZA200006166B (ru)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030220383A1 (en) * 2002-02-14 2003-11-27 Aventis Pharma Deutschland Gmbh Use of inhibitors of the sodium-dependent chloride/bicarbonate exchanger for the treatment of thrombotic and inflammatory disorders
DE10206354A1 (de) * 2002-02-14 2003-08-28 Aventis Pharma Gmbh Verwendung von Inhibitoren des Natrium-abhängigen Chlorid-Bicarbonat-Austauschers zur Behandlung von thrombotischen und inflammatorischer Erkrankungen
ITTO20060575A1 (it) * 2006-08-02 2008-02-03 Univ Pisa Inibitori di zinco proteinasi tioaril sostituiti e loro usi
WO2018002673A1 (en) 2016-07-01 2018-01-04 N4 Pharma Uk Limited Novel formulations of angiotensin ii receptor antagonists

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1334092C (en) * 1986-07-11 1995-01-24 David John Carini Angiotensin ii receptor blocking imidazoles
IL98319A (en) * 1990-07-05 1997-04-15 Roussel Uclaf Sulphurous derivatives of imidazole, their preparation process, and pharmaceutical compositions containing them
US5126342A (en) * 1990-10-01 1992-06-30 Merck & Co., Inc. Imidazole angiotensin ii antagonists incorporating acidic functional groups
CA2058198A1 (en) * 1991-01-04 1992-07-05 Adalbert Wagner Azole derivatives, process for their preparation, and their use
TW215434B (ru) * 1992-03-07 1993-11-01 Hoechst Ag
US5310929A (en) * 1992-08-06 1994-05-10 E. I. Du Pont De Nemours And Company Prodrugs of imidazole carboxylic acids as angiotensin II receptor antagonists
FR2711368B1 (fr) * 1993-09-16 1996-01-05 Roussel Uclaf Nouveau procédé de préparation de dérivés soufrés de l'imidazole et les nouveaux intermédiaires obtenus.
FR2716883B1 (fr) * 1994-03-04 1996-04-26 Roussel Uclaf Nouveaux dérivés tétrasubstitués de l'imidazole, leur préparation, nouveaux intermédiaires obtenus, leur application à titre de médicaments, compositions pharmaceutiques les renfermant.
DE19540995A1 (de) * 1995-11-03 1997-05-07 Hoechst Ag Substituierte Sulfonimidamide, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
EP0855392A3 (de) 1997-01-22 2000-01-05 Hoechst Aktiengesellschaft Fünfgliedrige Heterocyclen mit Biphenylsulfonylsubstitution, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
DE19741635A1 (de) * 1997-09-22 1999-03-25 Hoechst Marion Roussel De Gmbh Biphenylsulfonylcyanamide, Verfahren zu ihrer Herstellung und ihre Verwendung als Medikament
DE19804251A1 (de) 1998-02-04 1999-08-05 Hoechst Marion Roussel De Gmbh Biphenylsulfonylcyanamide, Verfahren zu ihrer Herstellung und ihre Verwendung als Medikament

Also Published As

Publication number Publication date
JP4546644B2 (ja) 2010-09-15
EP1076651B1 (de) 2005-04-20
HU225377B1 (en) 2006-10-28
DE59911949D1 (de) 2005-05-25
DE19980787D2 (de) 2001-03-22
WO1999057102A1 (de) 1999-11-11
CN1305463A (zh) 2001-07-25
AR016255A1 (es) 2001-06-20
SK16582000A3 (sk) 2001-06-11
CN1177829C (zh) 2004-12-01
ID28020A (id) 2001-05-03
NZ507964A (en) 2003-06-30
JP2002513785A (ja) 2002-05-14
AU5947999A (en) 1999-11-23
HUP0102459A2 (hu) 2002-03-28
BR9911009A (pt) 2001-02-13
CA2331863A1 (en) 1999-11-11
DE19820064A1 (de) 1999-11-11
IL139264A (en) 2004-07-25
KR20010043304A (ko) 2001-05-25
ATE293606T1 (de) 2005-05-15
HRP20000746A2 (en) 2001-06-30
IL139264A0 (en) 2001-11-25
TR200003248T2 (tr) 2001-03-21
HUP0102459A3 (en) 2002-12-28
US6573288B1 (en) 2003-06-03
PT1076651E (pt) 2005-08-31
EP1076651A1 (de) 2001-02-21
NO317886B1 (no) 2004-12-27
NO20005549L (no) 2001-01-05
PL344041A1 (en) 2001-09-24
AU756844B2 (en) 2003-01-23
ZA200006166B (en) 2001-09-26
DK1076651T3 (da) 2005-08-15
HK1038008A1 (en) 2002-03-01
NO20005549D0 (no) 2000-11-03
ES2241326T3 (es) 2005-10-16

Similar Documents

Publication Publication Date Title
RU2227143C2 (ru) Новые бициклонуклеозидные аналоги
RU2203890C2 (ru) Производные дигидронафталина
EP1477320A3 (en) Thermochromic color-memory composition and microencapsulated pigment containing the same
RU2001119455A (ru) Агрохимический состав
TNSN00191A1 (fr) Composes nouveaux, compositions les contenant et leur utilisation dans le traitement d'une ischemie
RU2221778C2 (ru) N-сульфонилглициналкинилоксифенэтиламидные производные, обладающие бактерицидной активностью
EP1777214A3 (en) Novel aryloxy-alkyl-dialkylamines
RU95112484A (ru) Производные 2,3,4,5-тетрагидро-1,4-бензотиазепинов, фармацевтическая композиция, способ лечения неврологических расстройств, припадков, способ защиты нервной системы, способ получения, использование
RU2221789C2 (ru) Замещенные сульфонилцианамиды и фармацевтическая препаративная форма
GB0210824D0 (en) Compounds
RU2005113661A (ru) Композиция, содержащая натриевую соль правастатина
DE3772135D1 (de) Phenolische korrosionsinhibitoren fuer anstrichstoffe.
JP2005526149A5 (ru)
DE69718244D1 (de) Chemische Phosphorylierung von Oligonukleotiden und Reagenz dafür
ES2109103T3 (es) Procedimiento para la preparacion de trialquilsilil-7 bacatina iii.
PT1224455E (pt) Processo de separacao de um composto quimico ou biologico numa mistura de compostos similares por difusao num meio tal como um gel
CA2247526A1 (fr) Cristaux de maltitol de formes particulieres, compositions cristallines les contenant et procedes pour leur preparation
BR9813923A (pt) N n - bis(sulfonil) hidrazinas úteis como agentes antineoplásicos
EP0855418A3 (en) High purity branched phenylsiloxane fluids
KR880005125A (ko) 7-((m-치환된)페닐글리신)1-카바-1-데티아세팔로스포린
RU2006101275A (ru) Нематоцидные тиазолинсодержащие фторбутены
RU2203283C1 (ru) Способ получения n-ацилированных алкил-(2-ацетил-2-диалкоксифосфорил)этанимидатов
RU2220721C2 (ru) Активный агент для ингибирования роста опухолей у млекопитающих, лечения и/или профилактики связанных с опухолями нарушений и метастаз опухолей у млекопитающих
JP2005528484A5 (ru)
KR927003583A (ko) 3-이미노-1,4-옥사티인 살균제

Legal Events

Date Code Title Description
PD4A Correction of name of patent owner
MM4A The patent is invalid due to non-payment of fees

Effective date: 20070501